{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:49:35Z","timestamp":1774079375617,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,15]]},"DOI":"10.1164\/rccm.201108-1565ed","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T06:24:03Z","timestamp":1321424643000},"page":"1096-1097","source":"Crossref","is-referenced-by-count":10,"title":["Reslizumab and Eosinophilic Asthma: One Step Closer to Phenotype-directed Therapy?"],"prefix":"10.1093","volume":"184","author":[{"given":"Jennifer W.","family":"McCallister","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Ohio State University Medical Center, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"2026032101201618100_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"3","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"4","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: assessment and identification using induced sputum","volume":"1","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"2026032101201618100_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(06)69290-8","article-title":"Asthma: defining of the persistent adult phenotypes","volume":"9537","author":"Wenzel","year":"2006","journal-title":"Lancet"},{"key":"2026032101201618100_bib5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"9347","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"2026032101201618100_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"5","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An Official ATS Clinical Practice Guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"5","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2273.2005.00969.x","article-title":"Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients","volume":"3","author":"Bateman","year":"2005","journal-title":"Clin Otolaryngol"},{"key":"2026032101201618100_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0091-6749(99)70118-1","article-title":"Eosinophilic airway inflammation in nasal polyposis","volume":"1","author":"Lamblin","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101201618100_bib11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"5","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101201618100_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"2","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"6","author":"Rosenberg","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101201618100_bib14","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"9248","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"2026032101201618100_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"11","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib16","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti- human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"12","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101201618100_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"10","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"2026032101201618100_bib18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"10","author":"Haldar","year":"2009","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/10\/1096\/67251319\/ajrccm_184_10_1096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/10\/1096\/67251319\/ajrccm_184_10_1096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:20:23Z","timestamp":1774070423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/184\/10\/1096\/8508357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,11,15]]},"published-print":{"date-parts":[[2011,11,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201108-1565ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,11]]},"published":{"date-parts":[[2011,11]]}}}